In what is obviously a naked attempt to drive up big pharma profits, Bourla said last week "a vaccine that will be taken once a year is way [easier] to administer and have the population be compliant with it, and we are working on that."
The CEO made his 'recommendation' during a press conference that was set up by the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) in which he talked about the creation of yet another new COVID vaccine.
“What the world really needs is a vaccine that can last a year,” he said, adding that the notion is part of what he termed "the optimal public-health solution" -- which, of course, assumes that COVID-19 is going to even be an annual problem (since SARS, MERS, and other coronaviruses that have appeared in the past were no more than one-time occurrences).
Asked by media press briefing host Claire Doole about whether he believes there will even be a need for an ongoing vaccine regime, Bourla responded in the affirmative, saying that COVID-19 is "very difficult to eradicate."
“The most likely scenario is that the virus will continue being with us for the years to come,” said Bourla, who appears to know something about the virus that most of us do not know.
After acknowledging that the current protection offered by the existing vaccines "is not long-lasting," the CEO complained about the lack of urgency among most people to take a follow-on booster shot, highlighting the shrinking number of people getting them after each booster is introduced (perhaps that's because the virus is fading fast).
“The issue is that right now we are in many, many countries in the fourth dose, and that creates a fatigue,” he said. “Way more people got the second [dose] than the third … [and] I think the compliance with the fourth dose will not be as high as we have had [previously]."
Strangely, however, he cited the lack of popularity for boosters as the primary reason why there should be an annual vaccine produced.
“[We] realized that people will not comply with the fourth or fifth vaccination … this is why we need to come [up with] scientific innovations that will allow us to have a vaccine that is annual," he said, going on to lament resistance to global COVID-19 restrictions and mandates, including vaccine requirements.
He then called the refusal to take the largely still experimental mRNA injections, which have caused millions of adverse reactions around the world, due to "politicization" of the shots, which he then said was damaging public health.
“I think that what didn’t help at all, and this was a very big issue, was the fact that there was a politicization,” he said. “It became a political statement [to get] a vaccine or [to] wear a mask or not, and that created tremendous damage to global health.”
The big pharma CEO was then asked about producing a vaccine that was more suited for the Omicron variant, but went on to talk about the potential of creating one vaccine that will address all known variants.
“It’s easy to do something only against Omicron,” he said. “What scientifically and technically is more challenging, but that we need to do, is to be effective against everything known so far.”
Asked if he believed that a vaccine could be ready by the fall of 2022, Bourla said "it is a possibility that we will have it by then" but that's "not a certainty."
He told the press conference that currently, he's waiting for "more data" before he will "make a decision" about what type of vaccine to produce.
“Once we have [more] data about that, it will allow us to make a decision as to which one is the best path forward, because in our studies right now we are testing different vaccines,” he said.
We don't need another annual vaccine, and certainly not one for a virus that is devolving. Bourla is just looking out for Pfizer's bottom line and he doesn't care if his product harms anyone.
Sources include:
Please contact us for more information.
